Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma.

Oncotarget · 2017 · PMC5581143 · PMID 28881844

Europe PMC DOI

hedged sentence

0.6300

closest p · 12.6× alpha

0.6300

boldest claim

The sentences

did not reach statistical significanceP = 0.630not close (p > 0.1)

Median PFS was 11.03 months in patients younger than 60 years (69 cases) and 6.5 months in those>60 years of age (31cases), although this difference did not reach statistical significance ( P = 0.630).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.